E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias∗—executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) Developed in Collaboration with NASPE-Heart Rhythm Society☆
TL;DR: In this paper, the authors present a set of guidelines for the diagnosis and management of supraventricular arrhythmias, which are intended to assist physicians in clinical decision-making by describing a range of generally acceptable approaches.
Journal ArticleDOI
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Jessica L. Mega,Sandra L Close,Stephen D. Wiviott,Lei Shen,Richard D. Hockett,John T. Brandt,Joseph R. Walker,Elliott M. Antman,William L. Macias,Eugene Braunwald,Marc S. Sabatine +10 more
TL;DR: Common functional CYP genetic variants do not affect active drug metabolite levels, inhibition of platelet aggregation, or clinical cardiovascular event rates in persons treated with prasugrel, and these pharmacogenetic findings are in contrast to observations with clopidogrel.
Journal ArticleDOI
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis
Jessica L. Mega,Sandra L Close,Sandra L Close,Stephen D. Wiviott,Lei Shen,Joseph R. Walker,Tabassome Simon,Elliott M. Antman,Eugene Braunwald,Marc S. Sabatine +9 more
TL;DR: Individuals with the ABCB1 3435C→T genotype have reduced platelet inhibition and are at increased risk of recurrent ischaemic events during clopidogrel treatment, and in patients with acute coronary syndromes who have undergone percutaneous intervention, this polymorphism is significantly associated with the risk of cardiovascular death, myocardial infarction, or stroke.
Journal ArticleDOI
ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary
Francis J. Klocke,Michael G. Baird,Beverly H. Lorell,Timothy M. Bateman,Joseph V. Messer,Daniel S. Berman,Patrick T. O'Gara,Blase A. Carabello,Richard O. Russell,Manuel D. Cerqueira,Martin St. John Sutton,Anthony N. DeMaria,James E. Udelson,J. Ward Kennedy,Mario S. Verani,Kim A. Williams,Elliott M. Antman,Sidney C. Smith,Joseph S. Alpert,Gabriel Gregoratos,Jeffrey L. Anderson,Loren F. Hiratzka,David P. Faxon,Sharon A. Hunt,Valentin Fuster,Alice K. Jacobs,Raymond J. Gibbons +26 more
TL;DR: The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines regularly reviews existing guidelines to determine when an update or full revision is needed as discussed by the authors.
Journal ArticleDOI
Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part II: Hemodynamic Effects and Clinical Applications
TL;DR: The negative inotropic effects of verapamil are valuable in improving the symptoms and hemodynamic disturbances of hypertrophic cardiomyopathy and the role of these agents in treating arterial hypertension, unstable angina pectoris, acute myocardial infarction, and ischemia during cardiopulmonary bypass needs to be determined.